関連する実験動画
Updated: May 5, 2026

11:45
Quantifying Agonist Activity at G Protein-coupled Receptors
Published on: December 26, 2011
18.5K
β(1) - アドレナゲン受容体に対するアゴニストおよび部分アゴニスト作用の構造的基礎
Tony Warne1, Rouslan Moukhametzianov, Jillian G Baker
1MRC Laboratory of Molecular Biology, Hills Road, Cambridge CB2 0QH, UK.
Nature
|January 14, 2011
まとめ
構造的な洞察は,異なるリガンドがベータアドレナリン受容体 (βARs) をどのように活性化するかを明らかにします. 完全アゴニストは,部分アゴニストとは異なり,主要なセリン残基を結合し,喘息や高血圧などの疾患に対する多様な治療効果を説明します.
科学分野:
- 構造生物学 構造生物学とは
- 薬理学 薬理学とは
- バイオケミストリー バイオケミストリー
背景:
- ベータアドレナリン受容体 (βARs) は,生理学的反応に不可欠なGタンパク質結合受容体 (GPCRs) である.
- βARを標的とする合成リガンドは,喘息,高血圧,心臓機能不全の治療に使用されます.
- リガンドの有効性の構造的基礎を理解することは,薬の開発に不可欠です.
研究 の 目的:
- βARリガンドの異なる有効性の基礎となる構造的メカニズムを解明する.
- 新規のGPCR標的治療法の合理的な設計のための構造的基盤を提供すること.
主な方法:
- X線結晶学を用いて,熱安定化されたトルコのβ(1) - アドレナゲン受容体 (β(1) AR-m23) の構造を決定した.
- 完全アゴニスト (カルモテロール,イソプレナリン) と部分アゴニスト (サルブタモール,ドブタミン) に結合する受容体の構造が得られました.
主要な成果:
- アゴニスト結合は,アゴニスト結合状態と比較して,カテキオラミン結合ポケットの1 Åの収縮を誘導した.
- 完全なアゴニストは,トランスメブランヘリックス5の2つの保存されたセリン残留物 (Ser5.42とSer5.46) と水素結合を形成した.
- 部分アゴニストは,Serと水素結合のみを形成し,その相互作用パターンを区別する.
結論:
- この研究は,βARsにおけるリガンドの有効性と相関する明確な構造的相互作用を明らかにしています.
- これらの発見は,GPCRの機能を明らかにし,適合した薬理学プロファイルを持つリガンドの構造ベースの設計のための基礎を提供します.
関連する概念動画
Drug-Receptor Interaction: Agonist
4.3K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
4.3K
Adrenergic Receptors (Adrenoceptors): Classification
4.9K
Adrenergic receptors, or adrenoceptors, respond to the autonomic neurotransmitter noradrenaline and other endogenous catecholamine agonists. They are classified into two main families, α and β, based on their pharmacological response and are further subdivided depending on their location, elicited response, and affinity to specific agonists or antagonists.
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors,...
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors,...
4.9K
Adrenergic Receptors: ɑ Subtype
2.7K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
2.7K
Adrenergic Receptors: β Subtype
3.8K
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
3.8K
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
3.9K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.9K
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
1.7K
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
1.7K

